Evidence map›Paper›PMID 39342123›Full record

ArticleBMC infectious diseases2024

Antimicrobial Sub-MIC induces Staphylococcus aureus biofilm formation without affecting the bacterial count.

Raghda Elawady, Aliaa G Aboulela, Ahmed Gaballah, Abeer A Ghazal, Ahmed N Amer

Erratum issuedAbstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Modulation ofInfection and drug resistance · 2026
    Article
  11. Sub-inhibitory tobramycin concentration suppresses ToxA and LipA in single- and dual-species biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Resveratrol inhibits the formation ofFrontiers in veterinary science · 2025
    Article
  17. Article
  18. Hexagonal zinc oxide nanoparticles: a novel approach to combat multidrug-resistantFrontiers in cellular and infection microbiology · 2024
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Raghda ElawadyDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt. mri.raghda.m.microbiology18@alexu.edu.eg.
Aliaa G AboulelaDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-2923-1027
Ahmed GaballahDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-9038-6597
Abeer A GhazalDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0001-8530-4879
Ahmed N AmerDepartment of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt.ORCID https://orcid.org/0000-0003-3610-4592

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiofilm formation is an essential virulence factor that creates a highly protected growth mode for Staphylococcus aureus (S. aureus) to survive in any hostile environment. Antibiotic sub-minimal inhibitory concentration (sub-MIC) may modulate the biofilm formation ability of bacterial pathogens, thereby affecting bacterial pathogenesis and infection outcomes. Intense antimicrobial therapy to treat biofilm-associated infections can control the pathogenic infection aggravation but cannot guarantee its complete eradication.

objectiveThis study aimed to assess the sub-MICs effect of 5 different antimicrobial classes on biofilm-forming capacity among Staphylococcus aureus clinical isolates using three different biofilm quantitation techniques.

methodsIn this study, the effects of 5 different antimicrobial agents, namely, azithromycin, gentamicin, ciprofloxacin, doxycycline, and imipenem, at sub-MICs of 12.5%, 25%, and 50% were tested on 5 different clinical isolates of S. aureus. The biofilms formed in the absence and presence of different antimicrobial sub-MICs were then assessed using the following three different techniques: the crystal violet (CV) staining method, the quantitative PCR (qPCR) method, and the spread plate method (SPM).

resultsBiofilm formation was significantly induced in 64% of the tested conditions using the CV technique. On the other hand, the qPCR quantifying the total bacterial count and the SPM quantifying the viable bacterial count showed significant induction only in 24% and 17.3%, respectively (Fig. 1). The difference between CV and the other techniques indicates an increase in biofilm biomass without an increase in bacterial growth. As expected, sub-MICs did not reduce the viable cell count, as shown by the SPM. The CV staining method revealed that sub-MICs of imipenem and ciprofloxacin had the highest significance rate (80%) showing an inductive effect on the biofilm development. On the other hand, doxycycline, azithromycin, and gentamicin displayed lower significance rates of 73%, 53%, and 47%, respectively.

conclusionExposure to sub-MIC doses of antimicrobial agents induces the biofilm-forming capacity of S. aureus via increasing the total biomass without significantly affecting the bacterial growth of viable count.

Indexed as

Anti-Bacterial AgentsBiofilmsMicrobial Sensitivity TestsStaphylococcal InfectionsStaphylococcus aureusBacterial LoadCiprofloxacinGentamicinsHumansAnti-Bacterial AgentsCiprofloxacinGentamicinsBiofilm biomassqPCRS. aureusSpread plate techniqueSubinhibitory concentration

Identifiers

PMID39342123
PMCPMC11438285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.